Adagene Inc. (ADAG)
- Simply Wall St.
Adagene Inc. (NASDAQ:ADAG) most popular amongst private equity firms who own 39% of the shares, institutions hold 30%
Key Insights Significant control over Adagene by private equity firms implies that the general public has more power to...
- GlobeNewswire
Adagene to Present at Investor Conferences in June
SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024. Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide a company update, including progress on the masked, anti-CTLA-4 SAFEbody® ADG126. Company management will also host investor meetin
- GlobeNewswire
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
- Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more frequent and repeat dosing of anti-CTLA-4 therapy in combination with anti-PD-1 - - Ongoing combination phase 2 dose expansion in MSS CRC increased to over 50 patients, including initiation of a new, unprecedented 20 mg/kg loading dose regimen, with data anticipated during 2024 -
